Taxanes are highly effective chemotherapeutic drugs against proliferating cancer and an established option in the standard treatment of ovarian and breast cancer. However, treatment with paclitaxel is associated with severe side effects, including sensory axonal neuropathy, and its poor solubility in water complicates its formulation. In this paper we report the in vitro and in vivo activity of a new form of paclitaxel, modified for conjugation with a tumor-selective tetrabranched peptide carrier (NT4). NT4 selectively targets tumor cells by binding to membrane sulfated glycosaminoglycans (GAG) and to endocytic receptors, like LRP1 and LRP6, which are established tumor markers. Biological activity of NT4-paclitaxel was tested in vitro on MDA-MB 231 and SKOV-3 cell lines, representing breast and ovarian cancer, respectively, and in vivo in an orthotopic mouse model of human breast cancer. Using in vivo bioluminescence imaging, we found that conjugation of paclitaxel with the NT4 peptide led to increased therapeutic activity of the drug in vivo. NT4-paclitaxel induced tumor regression, whereas treatment with unconjugated paclitaxel only produced a reduction in tumor growth. Moreover, unlike paclitaxel, NT4-paclitaxel is very hydrophilic, which may improve its pharmacokinetic profile and allow the use of less toxic dilution buffers, further decreasing its general chemotherapic toxicity.
|Titolo:||Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug|
|Citazione:||Brunetti, J., Pillozzi, S., Falciani, C., Depau, L., Tenori, E., Scali, S., et al. (2015). Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug. SCIENTIFIC REPORTS, 5, 1-9.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Articolo Brunetti et al., 2015, Scientific Reports.pdf||PDF editoriale||Open Access Visualizza/Apri|